ISPC (iSpecimen) EBITDA Margin % : -33.43% (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is iSpecimen EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. iSpecimen's EBITDA for the three months ended in Sep. 2024 was $-0.89 Mil. iSpecimen's Revenue for the three months ended in Sep. 2024 was $2.66 Mil. Therefore, iSpecimen's EBITDA margin for the quarter that ended in Sep. 2024 was -33.43%.

iSpecimen EBITDA Margin % Historical Data

The historical data trend for iSpecimen's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

iSpecimen EBITDA Margin % Chart

iSpecimen Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBITDA Margin %

Get a 7-Day Free Trial

-58.75

-21.21

-52.58

-84.62

-88.17

iSpecimen Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EBITDA Margin %	Get a 7-Day Free Trial															-56.98	-88.27	-100.48	-52.30	-33.43

Competitive Comparison of iSpecimen's EBITDA Margin %

For the Diagnostics & Research subindustry, iSpecimen's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

iSpecimen's EBITDA Margin % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, iSpecimen's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where iSpecimen's EBITDA Margin % falls into.

iSpecimen EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

iSpecimen's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %	=	EBITDA (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-8.754	/	9.928
	=	-88.17 %

iSpecimen's EBITDA Margin % for the quarter that ended in Sep. 2024 is calculated as

EBITDA Margin %	=	EBITDA (Q: Sep. 2024 )	/	Revenue (Q: Sep. 2024 )
	=	-0.89	/	2.662
	=	-33.43 %

iSpecimen (NAS:ISPC) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

iSpecimen EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of iSpecimen's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

iSpecimen Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » iSpecimen Inc (NAS:ISPC) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

450 Bedford Street, Lexington, MA, USA, 02420

Website

https://www.ispecimen.com

iSpecimen Inc is a technology-driven company focused on connecting life science researchers who need human biofluids, solid tissues, and hematopoietic stem and immune cells for their research, with the available biospecimens. The company generates revenue by procuring various specimens from hospitals, laboratories, and other supply sites. Geographically, it has a presence in the Americas; Europe, the Middle East, Africa, and Asia Pacific, which majority, comes from the Americas.

Executives

Benjamin Bielak	officer: Chief Information Officer	450 BEDFORD STREET, LEXINGTON MA 02420
Tracy Curley	officer: Chief Financial Officer	450 BEDFORD STREET, LEXINGTON MA 02420
Joseph J. Basile	director	450 BEDFORD STREET, LEXINGTON MA 02420
Andrew L. Ross	director, 10 percent owner	450 BEDFORD STREET, LEXINGTON MA 02420
Gullans Steven R. Ph.d.	director	C/O EXCEL VENTURE MANAGEMENT, LLC, 800 BOYLSTON ST., STE 2825, BOSTON MA 02199
John L Brooks	director	100 LOWDER BROOK DRIVE SUITE 2500, WESTWOOD MA 02090
Obf Investments, Llc	10 percent owner	450 BEDFORD STREET, LEXINGTON MA 02420
Margaret H. Lawrence	director	450 BEDFORD STREET, LEXINGTON MA 02420
George H. Scholl	director	450 BEDFORD STREET, LEXINGTON MA 02420
Christopher Ianelli	director, officer: CEO, President	450 BEDFORD STREET, LEXINGTON MA 02420
Jill Mullan	director, officer: COO, Secretary, Treasurer	450 BEDFORD STREET, LEXINGTON MA 02420